Workflow
Enlicitide Decanoate
icon
搜索文档
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Businesswire· 2025-11-09 03:30
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial. ...